Misplaced Pages

Hysterectomy
Diagram showing what is removed with a radical hysterectomy
Specialty	Gynaecology
ICD-9-CM	68.9
MeSH	D007044
MedlinePlus	002915
[edit on Wikidata]

Hysterectomy is the surgical removal of the uterus and cervix. Supracervical hysterectomy refers to removal of the uterus while the cervix is spared. These procedures may also involve removal of the ovaries (oophorectomy), fallopian tubes (salpingectomy), and other surrounding structures. The term “partial” or “total” hysterectomy are lay-terms that incorrectly describe the addition or omission of oophorectomy at the time of hysterectomy. These procedures are usually performed by a gynecologist. Removal of the uterus renders the patient unable to bear children (as does removal of ovaries and fallopian tubes) and has surgical risks as well as long-term effects, so the surgery is normally recommended only when other treatment options are not available or have failed. It is the second most commonly performed gynecological surgical procedure, after cesarean section, in the United States. Nearly 68 percent were performed for conditions such as endometriosis, irregular bleeding, and uterine fibroids. It is expected that the frequency of hysterectomies for non-malignant indications will continue to fall given the development of alternative treatment options.

Medical uses

Hysterectomy is a major surgical procedure that has risks and benefits. It affects the hormonal balance and overall health of patients. Because of this, hysterectomy is normally recommended as a last resort after pharmaceutical or other surgical options have been exhausted to remedy certain intractable and severe uterine/reproductive system conditions. There may be other reasons for a hysterectomy to be requested. Such conditions and/or indications include, but are not limited to:

• Endometriosis: growth of the uterine lining outside the uterine cavity. This inappropriate tissue growth can lead to pain and bleeding.
• Adenomyosis: a form of endometriosis, where the uterine lining has grown into and sometimes through the uterine wall musculature. This can thicken the uterine walls and also contribute to pain and bleeding.
• Heavy menstrual bleeding: irregular or excessive menstrual bleeding for greater than a week. It can disturb regular quality of life and may be indicative of a more serious condition.
• Uterine fibroids: benign growths on the uterus wall. These muscular noncancerous tumors can grow in single form or in clusters and can cause extreme pain and bleeding.
• Uterine prolapse: when the uterus sags down due to weakened or stretched pelvic floor muscles potentially causing the uterus to protrude out of the vagina in more severe cases.
• Reproductive system cancer prevention: especially if there is a strong family history of reproductive system cancers (especially breast cancer in conjunction with BRCA1 or BRCA2 mutation), or as part of recovery from such cancers.
• Gynecologic cancer: depending on the type of hysterectomy, can aid in treatment of cancer or precancer of the endometrium, cervix, or uterus. In order to protect against or treat cancer of the ovaries, would need an oophorectomy.
• Transgender (trans) male affirmation: aids in gender dysphoria, prevention of future gynecologic problems, and transition to obtaining new legal gender documentation.
• Severe developmental disabilities: this treatment is controversial at best. In the United States, specific cases of sterilization due to developmental disabilities have been found by state-level Supreme Courts to violate the patient's constitutional and common-law rights.
• Postpartum: to remove either a severe case of placenta praevia (a placenta that has either formed over or inside the birth canal) or placenta percreta (a placenta that has grown into and through the wall of the uterus to attach itself to other organs), as well as a last resort in case of excessive obstetrical haemorrhage.
• Chronic pelvic pain: should try to obtain pain etiology, although may have no known cause.
• PMS and menstrual pain and other psychic and physical conditions caused by menstrual period and causing suffering and diminishing life quality.

Risks and adverse effects

In 1995, the short-term mortality (within 40 days of surgery) was reported at 0.38 cases per 1000 when performed for benign causes. Risks for surgical complications were presence of fibroids, younger age (vascular pelvis with higher bleeding risk and larger uterus), dysfunctional uterine bleeding and parity.

The mortality rate is several times higher when performed in patients who are pregnant, have cancer or other complications.

Long-term effect on all case mortality is relatively small. Women under the age of 45 years have a significantly increased long-term mortality that is believed to be caused by the hormonal side effects of hysterectomy and prophylactic oophorectomy. This effect is not limited to pre-menopausal women; even women who have already entered menopause were shown to have experienced a decrease in long-term survivability post-oophorectomy.

Approximately 35% of women after hysterectomy undergo another related surgery within 2 years.

Ureteral injury is not uncommon and occurs in 0.2 per 1,000 cases of vaginal hysterectomy and 1.3 per 1,000 cases of abdominal hysterectomy. The injury usually occurs in the distal ureter close to the infundibulopelvic ligament or as a ureter crosses below the uterine artery, often from blind clamping and ligature placement to control hemorrhage.

Recovery

Hospital stay is 3 to 5 days or more for the abdominal procedure and between 1 and 2 days (but possibly longer) for vaginal or laparoscopically assisted vaginal procedures. After the procedure, the American College of Obstetricians and Gynecologists recommends not inserting anything into the vagina for the first 6 weeks (including inserting tampons or having sex).

Unintended oophorectomy and premature ovarian failure

Removal of one or both ovaries is performed in a substantial number of hysterectomies that were intended to be ovary sparing.

The average onset age of menopause after hysterectomy with ovarian conservation is 3.7 years earlier than average. This has been suggested to be due to the disruption of blood supply to the ovaries after a hysterectomy or due to missing endocrine feedback of the uterus. The function of the remaining ovaries is significantly affected in about 40% of people, some of them even require hormone replacement therapy. Surprisingly, a similar and only slightly weaker effect has been observed for endometrial ablation which is often considered as an alternative to hysterectomy.

A substantial number of women develop benign ovarian cysts after a hysterectomy.

Effects on sexual life and pelvic pain

After hysterectomy for benign indications the majority of patients report improvement in sexual life and pelvic pain. A smaller share of patients report worsening of sexual life and other problems. The picture is significantly different for hysterectomy performed for malignant reasons; the procedure is often more radical with substantial side effects. A proportion of patients who undergo a hysterectomy for chronic pelvic pain continue to have pelvic pain after a hysterectomy and develop dyspareunia (painful sexual intercourse).

Premature menopause and its effects

Estrogen levels fall sharply when the ovaries are removed, removing the protective effects of estrogen on the cardiovascular and skeletal systems. This condition is often referred to as "surgical menopause", although it is substantially different from a naturally occurring menopausal state; the former is a sudden hormonal shock to the body that causes rapid onset of menopausal symptoms such as hot flashes, while the latter is a gradually occurring decrease of hormonal levels over a period of years with uterus intact and ovaries able to produce hormones even after the cessation of menstrual periods.

One study showed that risk of subsequent cardiovascular disease is substantially increased for women who had hysterectomy at age 50 or younger. No association was found for women undergoing the procedure after age 50. The risk is higher when ovaries are removed but still noticeable even when ovaries are preserved.

Several other studies have found that osteoporosis (decrease in bone density) and increased risk of bone fractures are associated with hysterectomies. This has been attributed to the modulatory effect of estrogen on calcium metabolism and the drop in serum estrogen levels after menopause can cause excessive loss of calcium leading to bone wasting.

Hysterectomies have also been linked with higher rates of heart disease and weakened bones. Those who have undergone a hysterectomy with both ovaries removed typically have reduced testosterone levels as compared to those left intact. Reduced levels of testosterone in women are predictive of height loss, which may occur as a result of reduced bone density, while increased testosterone levels in women are associated with a greater sense of sexual desire.

Oophorectomy before the age of 45 is associated with a fivefold mortality from neurologic and mental disorders.

Urinary incontinence and vaginal prolapse

Urinary incontinence and vaginal prolapse are well known adverse effects that develop with high frequency a very long time after the surgery. Typically, those complications develop 10–20 years after the surgery. For this reason exact numbers are not known, and risk factors are poorly understood. It is also unknown if the choice of surgical technique has any effect. It has been assessed that the risk for urinary incontinence is approximately doubled within 20 years after hysterectomy. One long-term study found a 2.4 fold increased risk for surgery to correct urinary stress incontinence following hysterectomy.

The risk for vaginal prolapse depends on factors such as number of vaginal deliveries, the difficulty of those deliveries, and the type of labor. Overall incidence is approximately doubled after hysterectomy.

Adhesion formation and bowel obstruction

The formation of postoperative adhesions is a particular risk after hysterectomy because of the extent of dissection involved as well as the fact the hysterectomy wound is in the most gravity-dependent part of the pelvis into which a loop of bowel may easily fall. In one review, incidence of small bowel obstruction due to intestinal adhesion was found to be 15.6% in non-laparoscopic total abdominal hysterectomies vs. 0.0% in laparoscopic hysterectomies.

Wound infection

Wound infection occurs in approximately 3% of cases of abdominal hysterectomy. The risk is increased by obesity, diabetes, immunodeficiency disorder, use of systemic corticosteroids, smoking, wound hematoma, and preexisting infection such as chorioamnionitis and pelvic inflammatory disease. Such wound infections mainly take the form of either incisional abscess or wound cellulitis. Typically, both confer erythema, but only an incisional abscess confers purulent drainage. The recommended treatment of an incisional abscess after hysterectomy is by incision and drainage, and then coverage by a thin layer of gauze followed by sterile dressing. The dressing should be changed and the wound irrigated with normal saline at least twice each day. In addition, it is recommended to administer an antibiotic active against staphylococci and streptococci, preferably vancomycin when there is a risk of MRSA. The wound can be allowed to close by secondary intention. Alternatively, if the infection is cleared and healthy granulation tissue is evident at the base of the wound, the edges of the incision may be reapproximated, such as by using butterfly stitches, staples or sutures. Sexual intercourse remains possible after hysterectomy. Reconstructive surgery remains an option for women who have experienced benign and malignant conditions.

Other rare problems

Hysterectomy may cause an increased risk of the relatively rare renal cell carcinoma. The increased risk is particularly pronounced for young women; the risk was lower after vaginally performed hysterectomies. Hormonal effects or injury of the ureter were considered as possible explanations. In some cases the renal cell carcinoma may be a manifestation of an undiagnosed hereditary leiomyomatosis and renal cell cancer syndrome.

Removal of the uterus without removing the ovaries can produce a situation that on rare occasions can result in ectopic pregnancy due to an undetected fertilization that had yet to descend into the uterus before surgery. Two cases have been identified and profiled in an issue of the Blackwell Journal of Obstetrics and Gynecology; over 20 other cases have been discussed in additional medical literature. On very rare occasions, sexual intercourse after hysterectomy may cause a transvaginal evisceration of the small bowel. The vaginal cuff is the uppermost region of the vagina that has been sutured closed. A rare complication, it can dehisce and allow the evisceration of the small bowel into the vagina.

Alternatives

Depending on the indication there are alternatives to hysterectomy:

Heavy bleeding

Levonorgestrel intrauterine devices are highly effective at controlling dysfunctional uterine bleeding (DUB) or menorrhagia and should be considered before any surgery.

Menorrhagia (heavy or abnormal menstrual bleeding) may also be treated with the less invasive endometrial ablation which is an outpatient procedure in which the lining of the uterus is destroyed with heat, mechanically or by radio frequency ablation. Endometrial ablation greatly reduces or eliminates monthly bleeding in ninety percent of patients with DUB. It is not effective for patients with very thick uterine lining or uterine fibroids.

Uterine fibroids

Levonorgestrel intrauterine devices are highly effective in limiting menstrual blood flow and improving other symptoms. Side effects are typically very moderate because the levonorgestrel (a progestin) is released in low concentration locally. There is now substantial evidence that Levongestrel-IUDs provide good symptomatic relief for women with fibroids.

Uterine fibroids may be removed and the uterus reconstructed in a procedure called "myomectomy". A myomectomy may be performed through an open incision, laparoscopically, or through the vagina (hysteroscopy).

Uterine artery embolization (UAE) is a minimally invasive procedure for treatment of uterine fibroids. Under local anesthesia a catheter is introduced into the femoral artery at the groin and advanced under radiographic control into the uterine artery. A mass of microspheres or polyvinyl alcohol (PVA) material (an embolus) is injected into the uterine arteries in order to block the flow of blood through those vessels. The restriction in blood supply usually results in significant reduction of fibroids and improvement of heavy bleeding tendency. The 2012 Cochrane review comparing hysterectomy and UAE did not find any major advantage for either procedure. While UAE is associated with shorter hospital stay and a more rapid return to normal daily activities, it was also associated with a higher risk for minor complications later on. There were no differences between UAE and hysterectomy with regards to major complications.

Uterine fibroids can be removed with a non-invasive procedure called Magnetic Resonance guided Focused Ultrasound (MRgFUS).

Uterine prolapse

Prolapse may also be corrected surgically without removal of the uterus. There are several strategies that can be utilized to help strengthen pelvic floor muscles and prevent the worsening of prolapse. These include, but are not limited to, use of "kegel exercises", vaginal pessary, constipation relief, weight management, and care when lifting heavy objects.

Types

Hysterectomy, in the literal sense of the word, means merely removal of the uterus. However other organs such as ovaries, fallopian tubes, and the cervix are very frequently removed as part of the surgery.

• Radical hysterectomy: complete removal of the uterus, cervix, upper vagina, and parametrium. Indicated for cancer. Lymph nodes, ovaries, and fallopian tubes are also usually removed in this situation, such as in Wertheim's hysterectomy.
• Total hysterectomy: complete removal of the uterus and cervix, with or without oophorectomy.
• Subtotal hysterectomy: removal of the uterus, leaving the cervix in situ.

Subtotal (supracervical) hysterectomy was originally proposed with the expectation that it may improve sexual functioning after hysterectomy, it has been postulated that removing the cervix causes excessive neurologic and anatomic disruption, thus leading to vaginal shortening, vaginal vault prolapse, and vaginal cuff granulations. These theoretical advantages were not confirmed in practice, but other advantages over total hysterectomy emerged. The principal disadvantage is that risk of cervical cancer is not eliminated and women may continue cyclical bleeding (although substantially less than before the surgery). These issues were addressed in a systematic review of total versus supracervical hysterectomy for benign gynecological conditions, which reported the following findings:

• There was no difference in the rates of incontinence, constipation, measures of sexual function, or alleviation of pre-surgery symptoms.
• Length of surgery and amount of blood lost during surgery were significantly reduced during supracervical hysterectomy compared to total hysterectomy, but there was no difference in post-operative transfusion rates.
• Febrile morbidity was less likely and ongoing cyclic vaginal bleeding one year after surgery was more likely after supracervical hysterectomy.
• There was no difference in the rates of other complications, recovery from surgery, or readmission rates.

In the short-term, randomized trials have shown that cervical preservation or removal does not affect the rate of subsequent pelvic organ prolapse.

Supracervical hysterectomy does not eliminate the possibility of having cervical cancer since the cervix itself is left intact and may be contraindicated in women with increased risk of this cancer; regular pap smears to check for cervical dysplasia or cancer are still needed.

Technique

Hysterectomy can be performed in different ways. The oldest known technique is vaginal hysterectomy. The first planned hysterectomy was performed by Konrad Johann Martin Langenbeck - Surgeon General of the Hannovarian army, although there are records of vaginal hysterectomy for prolapse going back as far as 50BC.

The first abdominal hysterectomy recorded was by Ephraim McDowell. He performed the procedure in 1809 for a mother of five for a large ovarian mass on her kitchen table.

In modern medicine today, laparoscopic vaginal (with additional instruments passing through ports in small abdominal incisions, close or in the navel) and total laparoscopic techniques have been developed.

Abdominal hysterectomy

Most hysterectomies in the United States are done via laparotomy (abdominal incision, not to be confused with laparoscopy). A transverse (Pfannenstiel) incision is made through the abdominal wall, usually above the pubic bone, as close to the upper hair line of the individual's lower pelvis as possible, similar to the incision made for a caesarean section. This technique allows physicians the greatest access to the reproductive structures and is normally done for removal of the entire reproductive complex. The recovery time for an open hysterectomy is 4–6 weeks and sometimes longer due to the need to cut through the abdominal wall. Historically, the biggest problem with this technique was infections, but infection rates are well-controlled and not a major concern in modern medical practice. An open hysterectomy provides the most effective way to explore the abdominal cavity and perform complicated surgeries. Before the refinement of the vaginal and laparoscopic vaginal techniques, it was also the only possibility to achieve subtotal hysterectomy; meanwhile, the vaginal route is the preferable technique in most circumstances.

Vaginal hysterectomy

Vaginal hysterectomy is performed entirely through the vaginal canal and has clear advantages over abdominal surgery such as fewer complications, shorter hospital stays and shorter healing time. Abdominal hysterectomy, the most common method, is used in cases such as after caesarean delivery, when the indication is cancer, when complications are expected, or surgical exploration is required.

Laparoscopic-assisted vaginal hysterectomy

With the development of laparoscopic techniques in the 1970s and 1980s, the "laparoscopic-assisted vaginal hysterectomy" (LAVH) has gained great popularity among gynecologists because compared with the abdominal procedure it is less invasive and the post-operative recovery is much faster. It also allows better exploration and slightly more complicated surgeries than the vaginal procedure. LAVH begins with laparoscopy and is completed such that the final removal of the uterus (with or without removing the ovaries) is via the vaginal canal. Thus, LAVH is also a total hysterectomy; the cervix is removed with the uterus. If the cervix is removed along with the uterus, the upper portion of the vagina is sutured together and called the vaginal cuff.

Laparoscopic-assisted supracervical hysterectomy

The "laparoscopic-assisted supracervical hysterectomy" (LASH) was later developed to remove the uterus without removing the cervix using a morcellator which cuts the uterus into small pieces that can be removed from the abdominal cavity via the laparoscopic ports.

Total laparoscopic hysterectomy

Total laparoscopic hysterectomy (TLH) was developed in the early 90s by Prabhat K. Ahluwalia in Upstate New York. TLH is performed solely through the laparoscopes in the abdomen, starting at the top of the uterus, typically with a uterine manipulator. The entire uterus is disconnected from its attachments using long thin instruments through the "ports". Then all tissue to be removed is passed through the small abdominal incisions.

Other techniques

Supracervical (subtotal) laparoscopic hysterectomy (LSH) is performed similar to the total laparoscopic surgery but the uterus is amputated between the cervix and fundus.

Dual-port laparoscopy is a form of laparoscopic surgery using two 5 mm midline incisions: the uterus is detached through the two ports and removed through the vagina.

"Robotic hysterectomy" is a variant of laparoscopic surgery using special remotely controlled instruments that allow the surgeon finer control as well as three-dimensional magnified vision.

• Uterus prior to hysterectomy
• Laparoscopical hysterectomy
• Cervical stump (white) after removal of the uterine corpus at laparoscopic supracervical hysterectomy
• Transvaginal extraction of the uterus in total laparoscopical hysterectomy
• End of a laparoscopical hysterectomy

Comparison of techniques

Patient characteristics such as the reason for needing a hysterectomy, uterine size, descent of the uterus, presence of diseased tissues surrounding the uterus, previous surgery in the pelvic region, obesity, history of pregnancy, the possibility of endometriosis, or the need for an oophorectomy, will influence a surgeon's surgical approach when performing a hysterectomy.

Vaginal hysterectomy is recommended over other variants where possible for women with benign diseases. Vaginal hysterectomy was shown to be superior to LAVH and some types of laparoscopic surgery causing fewer short- and long-term complications, more favorable effect on sexual experience with shorter recovery times and fewer costs.

Laparoscopic surgery offers certain advantages when vaginal surgery is not possible but also has the disadvantage of significantly longer time required for the surgery.

In one 2004 study conducted in the UK comparing abdominal (laparotomic) and laparoscopic techniques, laparoscopic surgery was found to cause longer operation time and a higher rate of major complications while offering much quicker healing. In another study conducted in 2014, laparoscopy was found to be "a safe alternative to laparotomy" in patients receiving total hysterectomy for endometrial cancer. Researchers concluded the procedure "offers markedly improved perioperative outcomes with a lower reoperation rate and fewer postoperative complications when the standard of care shifts from open surgery to laparoscopy in a university hospital".

The abdominal technique is very often applied in difficult circumstances or when complications are expected. Given these circumstances the complication rate and time required for surgery compares very favorably with other techniques, however time required for healing is much longer.

Hysterectomy by abdominal laparotomy is correlated with much higher incidence of intestinal adhesions than other techniques.

Time required for completion of surgery in the eVAL trial is reported as follows:

• abdominal 55.2 minutes average, range 19–155
• vaginal 46.6 minutes average, range 14–168
• laparoscopic (all variants) 82.5 minutes average, range 10–325 (combined data from both trial arms)

Morcellation has been widely used especially in laparoscopic techniques and sometimes for the vaginal technique, but now appears to be associated with a considerable risk of spreading benign or malignant tumors. In April 2014, the FDA issued a memo alerting medical practitioners to the risks of power morcellation.

Robotic assisted surgery is presently used in several countries for hysterectomies. Additional research is required to determine the benefits and risks involved, compared to conventional laparoscopic surgery.

A 2014 Cochrane review found that robotic assisted surgery may have a similar complication rate when compared to conventional laparoscopic surgery. In addition, there is evidence to suggest that although the surgery make take longer, robotic assisted surgery may result in shorter hospital stays. More research is necessary to determine if robotic assisted hysterectomies are beneficial for people with cancer.

Previously reported marginal advantages of robotic assisted surgery could not be confirmed; only differences in hospital stay and cost remain statistically significant. In addition, concerns over widespread misleading marketing claims have been raised.

Incidence

Canada

In Canada, the number of hysterectomies between 2008 and 2009 was almost 47,000. The national rate for the same timeline was 338 per 100,000 population, down from 484 per 100,000 in 1997. The reasons for hysterectomies differed depending on whether the woman was living in an urban or rural location. Urban women opted for hysterectomies due to uterine fibroids and rural women had hysterectomies mostly for menstrual disorders.

United States

Hysterectomy is the second most common major surgery among women in the United States (the first is cesarean section). In the 1980s and 1990s, this statistic was the source of concern among some consumer rights groups and puzzlement among the medical community, and brought about informed choice advocacy groups like Hysterectomy Educational Resources and Services (HERS) Foundation, founded by Nora W. Coffey in 1982.

According to the National Center for Health Statistics, of the 617,000 hysterectomies performed in 2004, 73% also involved the surgical removal of the ovaries. There are currently an estimated 22 million women in the United States who have undergone this procedure. Nearly 68 percent were performed for benign conditions such as endometriosis, irregular bleeding and uterine fibroids. Such rates being highest in the industrialized world has led to the controversy that hysterectomies are being largely performed for unwarranted reasons. More recent data suggests that the number of hysterectomies performed has declined in every state in the United States. From 2010 to 2013, there were 12 percent fewer hysterectomies performed, and the types of hysterectomies were more minimally invasive in nature, reflected by a 17 percent increase in laparoscopic procedures.

United Kingdom

In the UK, 1 in 5 women is likely to have a hysterectomy by the age of 60, and ovaries are removed in about 20% of hysterectomies.

Germany

The number of hysterectomies in Germany has been constant for many years. In 2006, 149,456 hysterectomies were performed. Additionally, of these, 126,743 (84.8%) successfully benefitted the patient without incident. Women between the ages of 40 and 49 accounted for 50 percent of hysterectomies, and those between the ages of 50 and 59 accounted for 20 percent. In 2007, the number of hysterectomies decreased to 138,164. In recent years, the technique of laparoscopic or laparoscopically assisted hysterectomies has been raised into the foreground.

Denmark

In Denmark, the number of hysterectomies from the 1980s to the 1990s decreased by 38 percent. In 1988, there were 173 such surgeries per 100,000 women, and by 1998 this number had been reduced to 107. The proportion of abdominal supracervical hysterectomies in the same time period grew from 7.5 to 41 percent. A total of 67,096 women underwent hysterectomy during these years.

See also

• List of surgeries by type

References

1. ^ "Plotting the downward trend in traditional hysterectomy | Institute for Healthcare Policy & Innovation". ihpi.umich.edu. Retrieved 2019-08-06.
2. Bahamondes L, Bahamondes MV, Monteiro I (July 2008). "Levonorgestrel-releasing intrauterine system: uses and controversies". Expert Review of Medical Devices. 5 (4): 437–445. doi:10.1586/17434440.5.4.437. PMID 18573044. S2CID 659602.
3. "Hysterectomy". womenshealth.gov. 2017-02-21. Retrieved 2019-08-06.
4. Parasar P, Ozcan P, Terry KL (March 2017). "Endometriosis: Epidemiology, Diagnosis and Clinical Management". Current Obstetrics and Gynecology Reports. 6 (1): 34–41. doi:10.1007/s13669-017-0187-1. PMC 5737931. PMID 29276652.
5. "Uterine Adenomyosis". Yale Medicine. Retrieved 2022-10-31.
6. Uterine fibroids: Overview. Institute for Quality and Efficiency in Health Care (IQWiG). 2017-11-16.
7. Temkin SM, Bergstrom J, Samimi G, Minasian L (December 2017). "Ovarian Cancer Prevention in High-risk Women". Clinical Obstetrics and Gynecology. 60 (4): 738–757. doi:10.1097/GRF.0000000000000318. PMC 5920567. PMID 28957949.
8. "Hysterectomy | Transgender Care". transcare.ucsf.edu. Retrieved 2019-08-02.
9. Washington (state) Protection and Advocacy System. "Growth Attenuation and Sterilization Procedures – "The Ashley Treatment"". Washington, DC: National Disabilities Rights Network. Archived from the original on July 27, 2011. Retrieved 2011-03-10.
10. Roopnarinesingh R, Fay L, McKenna P (May 2003). "A 27-year review of obstetric hysterectomy". Journal of Obstetrics and Gynaecology. 23 (3): 252–254. doi:10.1080/0144361031000098352. PMID 12850853. S2CID 28253372.
11. Lamvu G (May 2011). "Role of hysterectomy in the treatment of chronic pelvic pain". Obstetrics and Gynecology. 117 (5): 1175–1178. doi:10.1097/AOG.0b013e31821646e1. PMID 21508759.
12. McPherson K, Metcalfe MA, Herbert A, Maresh M, Casbard A, Hargreaves J, et al. (July 2004). "Severe complications of hysterectomy: the VALUE study". BJOG. 111 (7): 688–694. doi:10.1111/j.1471-0528.2004.00174.x. PMID 15198759. S2CID 38391308.
13. Wingo PA, Huezo CM, Rubin GL, Ory HW, Peterson HB (August 1985). "The mortality risk associated with hysterectomy". American Journal of Obstetrics and Gynecology. 152 (7 Pt 1): 803–808. doi:10.1016/s0002-9378(85)80067-3. PMID 4025434.
14. Shuster LT, Gostout BS, Grossardt BR, Rocca WA (September 2008). "Prophylactic oophorectomy in premenopausal women and long-term health". Menopause International. 14 (3): 111–116. doi:10.1258/mi.2008.008016. PMC 2585770. PMID 18714076.
15. American Urogynecologic Society (May 5, 2015), "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation, American Urogynecologic Society, retrieved June 1, 2015, which cites: * Blank SV (February 2011). "Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer". Obstetrics and Gynecology. 117 (2 Pt 1): 404. doi:10.1097/AOG.0b013e3182083189. PMID 21252760.
16. Shoupe D, Parker WH, Broder MS, Liu Z, Farquhar C, Berek JS (2007). "Elective oophorectomy for benign gynecological disorders". Menopause. 14 (3 Pt 2): 580–585. doi:10.1097/gme.0b013e31803c56a4. PMID 17476148. S2CID 37549821.
17. Madueke-Laveaux OS, Elsharoud A, Al-Hendy A (November 2021). "What We Know about the Long-Term Risks of Hysterectomy for Benign Indication-A Systematic Review". Journal of Clinical Medicine. 10 (22): 5335. doi:10.3390/jcm10225335. PMC 8622061. PMID 34830617.
18. Burks FN, Santucci RA (June 2014). "Management of iatrogenic ureteral injury". Therapeutic Advances in Urology. 6 (3): 115–124. doi:10.1177/1756287214526767. PMC 4003841. PMID 24883109.
19. Ureteral Trauma at eMedicine
20. "Abdominal hysterectomy". Mayo Clinic.
21. "Hysterectomy". www.acog.org. Retrieved 2021-12-28.
22. ^ Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, von Mühlen D (February 2000). "Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study". The Journal of Clinical Endocrinology and Metabolism. 85 (2): 645–651. doi:10.1210/jcem.85.2.6405. PMID 10690870. S2CID 8195493.
23. Farquhar CM, Sadler L, Harvey SA, Stewart AW (July 2005). "The association of hysterectomy and menopause: a prospective cohort study". BJOG. 112 (7): 956–962. doi:10.1111/j.1471-0528.2005.00696.x. PMID 15957999. S2CID 21619116.
24. Bofill Rodriguez M, Lethaby A, Grigore M, Brown J, Hickey M, Farquhar C (January 2019). "Endometrial resection and ablation techniques for heavy menstrual bleeding". The Cochrane Database of Systematic Reviews. 1 (1): CD001501. doi:10.1002/14651858.CD001501.pub5. PMC 7057272. PMID 30667064.
25. Petri Nahás EA, Pontes A, Nahas-Neto J, Borges VT, Dias R, Traiman P (February 2005). "Effect of total abdominal hysterectomy on ovarian blood supply in women of reproductive age". Journal of Ultrasound in Medicine. 24 (2): 169–174. doi:10.7863/jum.2005.24.2.169. PMID 15661947. S2CID 30259666.
26. Maas CP, Weijenborg PT, ter Kuile MM (2003). "The effect of hysterectomy on sexual functioning". Annual Review of Sex Research. 14: 83–113. PMID 15287159.
27. Komisaruk BR, Frangos E, Whipple B (2011). "Hysterectomy improves sexual response? Addressing a crucial omission in the literature". Journal of Minimally Invasive Gynecology. 18 (3): 288–295. doi:10.1016/j.jmig.2011.01.012. PMC 3090744. PMID 21545957.
28. Gunter J (September 2003). "Chronic pelvic pain: an integrated approach to diagnosis and treatment". Obstetrical & Gynecological Survey. 58 (9): 615–623. doi:10.1097/01.OGX.0000083225.90017.01. PMID 12972837. S2CID 25101266.
29. Dalal PK, Agarwal M (July 2015). "Postmenopausal syndrome". Indian Journal of Psychiatry. 57 (Suppl 2): S222–S232. doi:10.4103/0019-5545.161483. PMC 4539866. PMID 26330639.
30. Ingelsson E, Lundholm C, Johansson AL, Altman D (March 2011). "Hysterectomy and risk of cardiovascular disease: a population-based cohort study". European Heart Journal. 32 (6): 745–750. doi:10.1093/eurheartj/ehq477. PMID 21186237.
31. Kelsey JL, Prill MM, Keegan TH, Quesenberry CP, Sidney S (November 2005). "Risk factors for pelvis fracture in older persons". American Journal of Epidemiology. 162 (9): 879–886. doi:10.1093/aje/kwi295. PMID 16221810.
32. van der Voort DJ, Geusens PP, Dinant GJ (2001). "Risk factors for osteoporosis related to their outcome: fractures". Osteoporosis International. 12 (8): 630–638. doi:10.1007/s001980170062. PMID 11580076. S2CID 9421669.
33. Jassal SK, Barrett-Connor E, Edelstein SL (April 1995). "Low bioavailable testosterone levels predict future height loss in postmenopausal women". Journal of Bone and Mineral Research. 10 (4): 650–654. doi:10.1002/jbmr.5650100419. PMID 7610937. S2CID 30094806.
34. Segraves R, Woodard T (May 2006). "Female hypoactive sexual desire disorder: History and current status". The Journal of Sexual Medicine. 3 (3): 408–418. doi:10.1111/j.1743-6109.2006.00246.x. PMID 16681466. S2CID 39458239.
35. Rivera CM, Grossardt BR, Rhodes DJ, Rocca WA (2009). "Increased mortality for neurological and mental diseases following early bilateral oophorectomy". Neuroepidemiology. 33 (1): 32–40. doi:10.1159/000211951. PMC 2697609. PMID 19365140.
36. Brown JS, Sawaya G, Thom DH, Grady D (August 2000). "Hysterectomy and urinary incontinence: a systematic review". Lancet. 356 (9229): 535–539. doi:10.1016/S0140-6736(00)02577-0. PMID 10950229. S2CID 213231.
37. Altman D, Granath F, Cnattingius S, Falconer C (October 2007). "Hysterectomy and risk of stress-urinary-incontinence surgery: nationwide cohort study". Lancet. 370 (9597): 1494–1499. doi:10.1016/S0140-6736(07)61635-3. PMID 17964350. S2CID 27132159.
38. McPherson K, Herbert A, Judge A, Clarke A, Bridgman S, Maresh M, Overton C (July 2005). "Self-reported bladder function five years post-hysterectomy". Journal of Obstetrics and Gynaecology. 25 (5): 469–475. doi:10.1080/01443610500235170. PMID 16183583. S2CID 38512052.
39. Lukanovic A, Drazic K (July 2010). "Risk factors for vaginal prolapse after hysterectomy". International Journal of Gynaecology and Obstetrics. 110 (1): 27–30. doi:10.1016/j.ijgo.2010.01.025. PMID 20362288. S2CID 24322065.
40. Altman D, Falconer C, Cnattingius S, Granath F (May 2008). "Pelvic organ prolapse surgery following hysterectomy on benign indications". American Journal of Obstetrics and Gynecology. 198 (5): 572.e1–572.e6. doi:10.1016/j.ajog.2008.01.012. PMID 18355787.
41. Wiseman DM (July 2008). "Disorders of adhesions or adhesion-related disorder: monolithic entities or part of something bigger--CAPPS?". Seminars in Reproductive Medicine. 26 (4): 356–368. CiteSeerX 10.1.1.628.2706. doi:10.1055/s-0028-1082394. PMID 18756413. S2CID 260317149.
42. ^ Barmparas G, Branco BC, Schnüriger B, Lam L, Inaba K, Demetriades D (October 2010). "The incidence and risk factors of post-laparotomy adhesive small bowel obstruction". Journal of Gastrointestinal Surgery. 14 (10): 1619–1628. doi:10.1007/s11605-010-1189-8. PMID 20352368. S2CID 22720831.
43. ^ Duff P (2009). "Diagnosis and Management of Postoperative Infection". The Global Library of Women's Medicine. doi:10.3843/GLOWM.10032. ISSN 1756-2228.
44. Hoffman B (2012). Williams gynecology, 2nd edition. New York: McGraw-Hill Medical. p. 65. ISBN 978-0071716727.
45. Altman D, Yin L, Johansson A, Lundholm C, Grönberg H (December 2010). "Risk of renal cell carcinoma after hysterectomy". Archives of Internal Medicine. 170 (22): 2011–2016. doi:10.1001/archinternmed.2010.425. PMID 21149759.
46. Gago-Dominguez M, Castelao JE, Yuan JM, Ross RK, Yu MC (November 1999). "Increased risk of renal cell carcinoma subsequent to hysterectomy". Cancer Epidemiology, Biomarkers & Prevention. 8 (11): 999–1003. PMID 10566555.
47. Zucchetto A, Talamini R, Dal Maso L, Negri E, Polesel J, Ramazzotti V, et al. (November 2008). "Reproductive, menstrual, and other hormone-related factors and risk of renal cell cancer". International Journal of Cancer. 123 (9): 2213–2216. doi:10.1002/ijc.23750. PMID 18711701. S2CID 45289039.
48. Cocks PS (May 1980). "Early ectopic pregnancy after vaginal hysterectomy. Two case reports". British Journal of Obstetrics and Gynaecology. 87 (5): 363–365. doi:10.1111/j.1471-0528.1980.tb04559.x. PMID 7387935. S2CID 27101990.
49. Quiróz-Guadarrama CD, Martínez-Ordaz JL, Rojano-Rodríguez ME, Beristain-Hernández JL, Moreno-Portillo M (June 2013). "". Ginecologia y Obstetricia de Mexico. 81 (6): 349–352. PMID 23837301.
50. Jelovsek JE, Maher C, Barber MD (March 2007). "Pelvic organ prolapse". Lancet. 369 (9566): 1027–1038. doi:10.1016/s0140-6736(07)60462-0. PMID 17382829. S2CID 38561018.
51. Milsom I (June 2007). "The levonorgestrel-releasing intrauterine system as an alternative to hysterectomy in peri-menopausal women". Contraception. 75 (6 Suppl): S152–S154. doi:10.1016/j.contraception.2007.01.003. PMID 17531608.
52. Bofill Rodriguez M, Lethaby A, Fergusson RJ (February 2021). "Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding". The Cochrane Database of Systematic Reviews. 2021 (2): CD000329. doi:10.1002/14651858.CD000329.pub4. PMC 8095059. PMID 33619722.
53. Pesmen C (July 27, 2007). "5 operations you don't want to get – and what to do instead". CNN.
54. Zapata LB, Whiteman MK, Tepper NK, Jamieson DJ, Marchbanks PA, Curtis KM (July 2010). "Intrauterine device use among women with uterine fibroids: a systematic review". Contraception. 82 (1): 41–55. doi:10.1016/j.contraception.2010.02.011. PMID 20682142.
55. Parker WH, Parker RL (2002). A Gynecologist's Second Opinion: The Questions & Answers You Need to Take Charge of Your Health (revised ed.). Plume. pp. 89–92, 105–150. Archived from the original on 2007-06-09.
56. Laios A, Baharuddin N, Iliou K, Gubara E, O'Sullivan G (2014). "Uterine artery embolization for treatment of symptomatic fibroids; a single institution experience". Hippokratia. 18 (3): 258–261. PMC 4309148. PMID 25694762.
57. Gupta JK, Sinha A, Lumsden MA, Hickey M (December 2014). "Uterine artery embolization for symptomatic uterine fibroids". The Cochrane Database of Systematic Reviews (12): CD005073. doi:10.1002/14651858.CD005073.pub4. PMC 11285296. PMID 25541260.
58. Jelovsek FR. "Having Prolapse, Cystocele and Rectocele Fixed Without Hysterectomy". Women's Health. wdxcyber.com.
59. "Hysterectomy". womenshealth.gov. 2017-02-21. Retrieved 2019-08-01.
60. "Complete Hysterectomy". www.cancer.gov. 2011-02-02. Retrieved 2022-10-31.
61. encyclopedia.com > Wertheim's hysterectomy Citing: "Wertheim's hysterectomy". A Dictionary of Nursing. 2008. Encyclopedia.com. (October 13, 2010).
62. Greer WJ, Richter HE, Wheeler TL, Varner RE, Szychowski JM, Kuppermann M, Learman LA (January 2010). "Long-Term Outcomes of the Total or Supracervical Hysterectomy (TOSH) Trial". Female Pelvic Medicine & Reconstructive Surgery. 16 (1): 49–57. doi:10.1097/SPV.0b013e3181cec343. PMC 3252027. PMID 22229107.
63. Lethaby A, Mukhopadhyay A, Naik R (April 2012). Lethaby A (ed.). "Total versus subtotal hysterectomy for benign gynaecological conditions". The Cochrane Database of Systematic Reviews. 4 (4): CD004993. doi:10.1002/14651858.CD004993.pub3. PMID 22513925.
64. ^ Müller A, Thiel FC, Renner SP, Winkler M, Häberle L, Beckmann MW (May 2010). "Hysterectomy-a comparison of approaches". Deutsches Ärzteblatt International. 107 (20): 353–359. doi:10.3238/arztebl.2010.0353. PMC 2883234. PMID 20539807.
65. Thakar R, Ayers S, Clarkson P, Stanton S, Manyonda I (October 2002). "Outcomes after total versus subtotal abdominal hysterectomy". The New England Journal of Medicine. 347 (17): 1318–1325. doi:10.1056/NEJMoa013336. PMID 12397189.
66. American Academy of Family Physicians (April 2012). "Five Things Physicians and Patients Should Question" (PDF). Choosing Wisely: An Initiative of the ABIM Foundation. American Academy of Family Physicians. Archived from the original (PDF) on June 24, 2012. Retrieved August 14, 2012.
67. Consumer Reports; American Academy of Family Physicians (May 2012). "Pap tests: When you need them—and when you don't" (PDF). Choosing Wisely: An Initiative of the ABIM Foundation. Consumer Reports. Archived from the original (PDF) on June 24, 2012. Retrieved August 17, 2012.
68. Pillarisetty LS, Mahdy H (2022). "Vaginal Hysterectomy". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 32119369. Retrieved 2022-10-31.
69. "Hysterectomy: Then and Now - Oxford Women's Health". www.oxfordwomenshealth.co.nz. Archived from the original on 2023-10-17. Retrieved 2020-01-27.
70. Alazzam M, Khalifa MA, Al-Ani A (May 2022). "The transverse-vertical incision (Alazzam hybrid incision)". Langenbeck's Archives of Surgery. 407 (3): 1303–1309. doi:10.1007/s00423-021-02404-5. PMC 9151581. PMID 35226178.
71. ^ Thomas B, Magos A (April 2011). "Subtotal hysterectomy and myomectomy - vaginally". Best Practice & Research. Clinical Obstetrics & Gynaecology. 25 (2): 133–152. doi:10.1016/j.bpobgyn.2010.11.003. PMID 21185235.
72. ^ Sheth SS, Paghdiwalla KP, Hajari AR (April 2011). "Vaginal route: a gynaecological route for much more than hysterectomy". Best Practice & Research. Clinical Obstetrics & Gynaecology. 25 (2): 115–132. doi:10.1016/j.bpobgyn.2010.12.005. PMID 21349773.
73. ^ Johnson N, Barlow D, Lethaby A, Tavender E, Curr L, Garry R (June 2005). "Methods of hysterectomy: systematic review and meta-analysis of randomised controlled trials". BMJ. 330 (7506): 1478. doi:10.1136/bmj.330.7506.1478. PMC 558455. PMID 15976422.
74. Pickett CM, Seeratan DD, Mol BW, Nieboer TE, Johnson N, Bonestroo T, Aarts JW (August 2023). "Surgical approach to hysterectomy for benign gynaecological disease". The Cochrane Database of Systematic Reviews. 2023 (8): CD003677. doi:10.1002/14651858.CD003677.pub6. PMC 10464658. PMID 37642285.
75. "Surgery - Foundation for Women's Cancer". Foundation for Women's Cancer. Archived from the original on 2018-11-07. Retrieved 2018-11-07.
76. Cronin B, Sung VW, Matteson KA (April 2012). "Vaginal cuff dehiscence: risk factors and management". American Journal of Obstetrics and Gynecology. 206 (4): 284–288. doi:10.1016/j.ajog.2011.08.026. PMC 3319233. PMID 21974989.
77. Devassy R, Cezar C, Krentel H, Verhoeven HC, Devassy R, de Wilde MS, et al. (February 2019). "Feasibility of myomatous tissue extraction in laparoscopic surgery by contained in - bag morcellation: A retrospective single arm study". International Journal of Surgery. 62: 22–27. doi:10.1016/j.ijsu.2018.12.013. PMID 30639472. S2CID 58564050.
78. Ahluwalia PK (August 1996). "Total Laparoscopic Hysterectomy". The Journal of the American Association of Gynecologic Laparoscopists. 3 (4, Supplement): S1–S2. doi:10.1016/S1074-3804(96)80129-0. PMID 9074073.
79. Cipullo L, De Paoli S, Fasolino L, Fasolino A (2009). "Laparoscopic supracervical hysterectomy compared to total hysterectomy". JSLS. 13 (3): 370–375. PMC 3015973. PMID 19793479.
80. Lii SJ, Becker SF, Danilyants NE, MacKoul PJ (2010). "A Novel Approach to Total Laparoscopic Hysterectomy Using Only Two 5mm Ports: Initial Clinical Experience". Journal of Minimally Invasive Gynecology. 17 (6): S87. doi:10.1016/j.jmig.2010.08.381.
81. Moawad G, Robinson JK (2012). "Dual Port Hysterectomy: A Novel Technique and Initial Experience". Journal of Minimally Invasive Gynecology. 19 (6): S86. doi:10.1016/j.jmig.2012.08.620.
82. "Robotic surgery: MedlinePlus Medical Encyclopedia". medlineplus.gov.
83. ^ Aarts JW, Nieboer TE, Johnson N, Tavender E, Garry R, Mol BW, Kluivers KB (August 2015). "Surgical approach to hysterectomy for benign gynaecological disease". The Cochrane Database of Systematic Reviews. 2015 (8): CD003677. doi:10.1002/14651858.CD003677.pub5. hdl:2066/154037. PMC 6984437. PMID 26264829.
84. Stovall TG, Summitt RL (August 1996). "Laparoscopic hysterectomy--is there a benefit?". The New England Journal of Medicine. 335 (7): 512–513. doi:10.1056/NEJM199608153350712. PMID 8672159.
85. "Laparoscopic Hysterectomy and Health Care in America – Finding the Balance Between Costs and Outcomes". Archived from the original on 2010-07-17. Retrieved 2010-01-24.
86. Debodinance P (April 2001). "". Journal de Gynécologie, Obstétrique et Biologie de la Reproduction. 30 (2): 151–159. PMID 11319467.
87. ^ Garry R, Fountain J, Mason S, Hawe J, Napp V, Abbott J, et al. (January 2004). "The eVALuate study: two parallel randomised trials, one comparing laparoscopic with abdominal hysterectomy, the other comparing laparoscopic with vaginal hysterectomy". BMJ. 328 (7432): 129–0. doi:10.1136/bmj.37984.623889.F6. PMC 314503. PMID 14711749.
88. Boosz A, Haeberle L, Renner SP, Thiel FC, Mehlhorn G, Beckmann MW, Mueller A (December 2014). "Comparison of reoperation rates, perioperative outcomes in women with endometrial cancer when the standard of care shifts from open surgery to laparoscopy". Archives of Gynecology and Obstetrics. 290 (6): 1215–1220. doi:10.1007/s00404-014-3347-9. PMID 25009071. S2CID 25074196.
89. Seidman MA, Oduyebo T, Muto MG, Crum CP, Nucci MR, Quade BJ (2012). Sullivan DJ (ed.). "Peritoneal dissemination complicating morcellation of uterine mesenchymal neoplasms". PLOS ONE. 7 (11): e50058. Bibcode:2012PLoSO...750058S. doi:10.1371/journal.pone.0050058. PMC 3506532. PMID 23189178.
90. Cucinella G, Granese R, Calagna G, Somigliana E, Perino A (August 2011). "Parasitic myomas after laparoscopic surgery: an emerging complication in the use of morcellator? Description of four cases". Fertility and Sterility. 96 (2): e90–e96. doi:10.1016/j.fertnstert.2011.05.095. hdl:10447/77912. PMID 21719004.
91. "Safety Communications – UPDATED Laparoscopic Uterine Power Morcellation in Hysterectomy and Myomectomy: FDA Safety Communication". Center for Devices and Radiological Health. U.S. Food and Drug Administration. Retrieved 2017-01-10.
92. ^ Lawrie TA, Liu H, Lu D, Dowswell T, Song H, Wang L, Shi G (April 2019). "Robot-assisted surgery in gynaecology". The Cochrane Database of Systematic Reviews. 4 (4): CD011422. doi:10.1002/14651858.CD011422.pub2. PMC 6464707. PMID 30985921.
93. ^ Wright JD, Ananth CV, Lewin SN, Burke WM, Lu YS, Neugut AI, et al. (February 2013). "Robotically assisted vs laparoscopic hysterectomy among women with benign gynecologic disease". JAMA. 309 (7): 689–698. doi:10.1001/jama.2013.186. PMID 23423414.
94. Soto E, Lo Y, Friedman K, Soto C, Nezhat F, Chuang L, Gretz H (December 2011). "Total laparoscopic hysterectomy versus da Vinci robotic hysterectomy: is using the robot beneficial?". Journal of Gynecologic Oncology. 22 (4): 253–259. doi:10.3802/jgo.2011.22.4.253. PMC 3254844. PMID 22247802.
95. Ridgeway BM, Buechel M, Nutter B, Falcone T (December 2015). "Minimally Invasive Hysterectomy: An Analysis of Different Techniques". Clinical Obstetrics and Gynecology. 58 (4): 732–739. doi:10.1097/GRF.0000000000000149. PMID 26457851. S2CID 42747985.
96. Schiavone MB, Kuo EC, Naumann RW, Burke WM, Lewin SN, Neugut AI, et al. (September 2012). "The commercialization of robotic surgery: unsubstantiated marketing of gynecologic surgery by hospitals". American Journal of Obstetrics and Gynecology. 207 (3): 174.e1–174.e7. doi:10.1016/j.ajog.2012.06.050. PMID 22835493.
97. Blikkendaal MD, Schepers EM, van Zwet EW, Twijnstra AR, Jansen FW (October 2015). "Hysterectomy in very obese and morbidly obese patients: a systematic review with cumulative analysis of comparative studies". Archives of Gynecology and Obstetrics. 292 (4): 723–738. doi:10.1007/s00404-015-3680-7. PMC 4560773. PMID 25773357.
98. ^ King CR, Giles D (September 2016). "Total Laparoscopic Hysterectomy and Laparoscopic-Assisted Vaginal Hysterectomy". Obstetrics and Gynecology Clinics of North America. 43 (3): 463–478. doi:10.1016/j.ogc.2016.04.005. PMID 27521879.
99. ^ Nesbitt-Hawes EM, Maley PE, Won HR, Law KS, Zhang CS, Lyons SD, et al. (2013). "Laparoscopic subtotal hysterectomy: evidence and techniques". Journal of Minimally Invasive Gynecology. 20 (4): 424–434. doi:10.1016/j.jmig.2013.01.009. PMID 23510954.
100. ^ Lethaby A, Mukhopadhyay A, Naik R (April 2012). "Total versus subtotal hysterectomy for benign gynaecological conditions". The Cochrane Database of Systematic Reviews. 4 (4): CD004993. doi:10.1002/14651858.CD004993.pub3. PMID 22513925.
101. "Hysterectomy rates falling: report". CBC News. 2010-05-27. Retrieved 2010-05-28.
102. Kolata, Gina (1988-09-20). "Rate of Hysterectomies Puzzles Experts". The New York Times.
103. Masters C (2006-07-01). "Are Hysterectomies Too Common?". Time. Retrieved 2007-07-17.
104. "Hysterectomy Procedures Pacing A Downward Trend". labblog.uofmhealth.org. 23 January 2018. Retrieved 2019-08-06.
105. Khastgir G, Studd J (1998). Hysterectomy and HRT. Taylor & Francis. p. 3. ISBN 978-1-85317-408-7.
106. Wolfrum C (1 June 2008). "Vorschnelle Schnitte". Apotheken Umschau. Baierbrunn: Wort & Bild Verlag.
107. Mettler L, Ahmed-Ebbiary N, Schollmeyer T (2005). "Laparoscopic hysterectomy: challenges and limitations". Minimally Invasive Therapy & Allied Technologies. 14 (3): 145–159. doi:10.1080/13645700510034010. PMID 16754157. S2CID 25696299.
108. Jäger C, Sauer G, Kreienberg R (2007). "Die laparoskopisch assistierte vaginale Hysterektomie – Sinn oder Unsinn?". Geburtshilfe und Frauenheilkunde. 67 (6): 628–632. doi:10.1055/s-2007-965243. S2CID 260157584.
109. Gimbel H, Settnes A, Tabor A (March 2001). "Hysterectomy on benign indication in Denmark 1988-1998. A register based trend analysis". Acta Obstetricia et Gynecologica Scandinavica. 80 (3): 267–272. doi:10.1080/j.1600-0412.2001.080003267.x. PMID 11207494.

External links

• MedlinePlus Encyclopedia: Hysterectomy
• Oncolex.org features live footage videos showing radical hysterctomies Archived 2017-09-14 at the Wayback Machine
• Hudson's FTM Resource Guide, "FTM Gender Reassignment Surgery

• Masculinizing surgery
• Gynaecology
• Gynecological surgery
• Reproductive system
• Sterilization (medicine)
• Surgical oncology
• Surgical removal procedures